Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorPoyraz, Mehmet
dc.contributor.authorBerber, Halil
dc.contributor.authorBanti, Christina N.
dc.contributor.authorKourkoumelis, Nikolaos
dc.contributor.authorManos, Manolis J.
dc.contributor.authorHadjikakou, Sotiris K.
dc.date.accessioned2019-10-20T09:02:57Z
dc.date.available2019-10-20T09:02:57Z
dc.date.issued2017
dc.identifier.issn0277-5387
dc.identifier.urihttps://dx.doi.org/10.1016/j.poly.2017.03.011
dc.identifier.urihttps://hdl.handle.net/11421/16576
dc.descriptionWOS: 000401047100012en_US
dc.description.abstractThe treatment with triphenylphosphine (TPP) in DMF solution of the white precipitation derived from the reaction of silver(I) nitrate with 2-benzimidazolylurea (BZIMU) results in the [Ag(TPP)(2)(BZIMU)NO3] (1) complex. The product was characterized by elemental analysis and spectroscopic techniques (FT-IR and H-1, C-13 NMR). Single crystal X-ray diffraction analysis of 1 have been carried out at 293 K. Mixed ligand complexes of silver(I) nitrate with urea derivatives and phosphines which exhibits significant biological effects are rare in the literature. Complex 1 was evaluated for its in vitro cytotoxic activity (cell viability) against: (i) human breast adenocarcinoma cancer cell line (MCF-7) and (ii) normal human fetal lung fibroblast cells (MRC-5) with SRB assay. The results showed that 1 mediates a strong cytotoxic response to the tested normal (MRC-5) and cancer cell lines (MCF-7). It is also exhibits four time stronger activity against cancer cells (MCF-7) than cisplatin while it is less toxic against normal cells (MRC-5). The therapeutic potency index (TPI) which is define as the IC50 value of 1 against normal cells divided by its IC50 value against cancerous cells is 0.9 in contrast to the 0.2 of cisplatin. The influence of the complex 1, upon the catalytic peroxidation of linoleic acid to hydroperoxylinoleic acid by the enzyme lipoxygenase (LOX) was kinetically and theoretically studieden_US
dc.description.sponsorshipOncology Department of Novartis Hellas S.A.C.I. [81939]en_US
dc.description.sponsorshipThe authors acknowledge Scientific and Technological Research Application and Research Center, Sinop University, Turkey, for the use of the Bruker D8 QUEST diffractometer. The Unit of Bioactivity Testing of Xenobiotics, of the University of Ioannina-Greece, is also acknowledge for providing access to the facilities. SKIT acknowledge the Oncology Department of Novartis Hellas S.A.C.I. for the financial support (project number: 81939)en_US
dc.language.isoengen_US
dc.publisherPergamon-Elsevier Science LTDen_US
dc.relation.isversionof10.1016/j.poly.2017.03.011en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiological Inorganic Chemistryen_US
dc.subjectSilver(I) Metallo-Drugsen_US
dc.subjectUrea Derivativeen_US
dc.subjectCells Screeningen_US
dc.subjectCrystal Structureen_US
dc.titleSynthesis characterization and biological activity of mixed ligand silver(I) complex of 2-benzimidazolylurea and triphenylphosphineen_US
dc.typearticleen_US
dc.relation.journalPolyhedronen_US
dc.contributor.departmentAnadolu Üniversitesi, Fen Fakültesi, Fizik Bölümüen_US
dc.identifier.volume128en_US
dc.identifier.startpage95en_US
dc.identifier.endpage103en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.contributor.institutionauthorBerber, Halil


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster